@LonSchneiderMD Profile picture

Lon S. Schneider, MD

@LonSchneiderMD

University of Southern California, Alzheimer Disease Research Center

Similar User
Liana Apostolova, MD, MSc, FAAN photo

@ApostolovaLiana

CTAD photo

@CTADconference

Alzforum photo

@alzforum

ISTAART photo

@ISTAART

jpreventionalzheimer photo

@jpreventionalz1

Rachel Buckley 🐨🇦🇺🐨 photo

@bucklr01

World Dementia Council photo

@WorldDementia

Oskar Hansson photo

@OskarHansson9

Maria C Carrillo PhD photo

@DrMariaALZ

Nicolas Villain / Moved to LinkedIn photo

@nvillain_alz

Alzheimer's Therapeutic Research Institute photo

@ATRI_USC

Lea T. Grinberg, M.D, Ph.D photo

@grinberg_t

BioFINDER photo

@biofinder_study

Ana Capuano photo

@DrAnaCapuano

AD/PD - Advances in Science & Therapy photo

@adpdnet

Oct 22 2024, “the totality of the data supports the potential of HGF modulation for the treatment of neurodegenerative diseases” Javier San Martin CMO Nov 7 “Athira has paused further development of fosgonimeton…and are exploring partnering options” What changed in two weeks?

Head-to-head comparison of leading blood tests for Alzheimer's disease pathology alz-journals.onlinelibrary.wiley.com/doi/10.1002/al… via @SuzanneESchind1 et al



Lon S. Schneider, MD Reposted

"Gantenerumab significantly increased CSF Aβ42 compared to placebo at year 4 (Supplementary Fig. 5, P < 0.001)" nature.com/articles/s4159…

Tweet Image 1

On Wednesday at 415p in #Philadelphia the @TheLancet commission on dementia diagnosis prevention and treatment will present its 3rd report at the #AAIC24 #AAIC2024 beginning of there or be square Or you can see Arsenal play Liverpool at Lincoln Field in Philadelphia.


Tip of the iceberg. This kind of fraud tends to pay as it gets the molecule through pre- & clinical tox & into phase 2/3 trials that could easily be positive on an outcome by chance alone, or hook and crook. Anyway, Cassava will have him pardoned on January 20 if they pay up.

Professor Charged for Operating Multimillion-Dollar Grant Fraud Scheme Wang allegedly engaged in a scheme to fabricate and falsify scientific data in grant applications made to the NIH on behalf of himself and the biopharmaceutical company. $SAVA justice.gov/opa/pr/profess…



Lon S. Schneider, MD Reposted

Many rushed to shame @DukeU for what happened today, at the Graduation ceremony - a bunch of pro-palestine students booed Jerry Seinfeld and left before his speech. I know from personal sources that Duke handled exemplary the whole anti-jewish ordeal. There were no encampments,…


Lon S. Schneider, MD Reposted

Wow. Joe Scarborough just decimated Donald Trump, the Republican Party, and Fox News in under 3 minutes for constantly hating America. Blown away by how well said this was. Certainly worth a watch👇


Lilly $LLY shareholders? That’s vanguard, fidelity, black rock, state street, jpm, anyone with a 401(k), pretty much all of us. I should start acting like an owner? FDA! Free donanemab! From coast to coast, ocean to ocean, river to sea?

Please consider Eli Lilly shareholders.



Sorry, this is disease modifying (if you thought the graph was of an antibody). As “everyone knows” cholinesterase inhibitors are symptomatic, then this donepezil graph must be showing a symptomatic effect. It just can’t be otherwise.

Neurology's most enduring, always shattered dream: diverging slopes between treatments within the window of trials predict greater effects beyond them. (1/5) Donepezil: had it not been for the washout period, this 24-week trial seemed disease-modifying. neurology.org/doi/10.1212/wn…

Tweet Image 1


The only reason for the divergence at all was the zeroing out of the baseline with multiple covariate adjustments. As both curves started at the same value, definitionally, they had to diverge.

(4/5) Longer studies are more helpful in this regard. Donanemab, the latest 'disease-modifying' anti-Aβ monoclonal antibody, led to perfectly parallel slopes of decline --after a period of divergence. nejm.org/doi/full/10.10…

Tweet Image 1


Looks like open label extension of p3 lecanemab’s low tau subset. I’m sure there’s disease modification there somewhere.

(2/5) Galantamine: at 1-year, slopes diverge. The open-label extension clarified the divergence was not sustained. (square = galantamine; diamond = placebo). neurology.org/doi/10.1212/wn…

Tweet Image 1


Looks like extension of phase 2 lecanemab withdrawal period and phase 3’s open label extension.

Neurology's most enduring, always shattered dream: diverging slopes between treatments within the window of trials predict greater effects beyond them. (1/5) Donepezil: had it not been for the washout period, this 24-week trial seemed disease-modifying. neurology.org/doi/10.1212/wn…

Tweet Image 1


Lon S. Schneider, MD Reposted

Thanks for communicating this. Since we have cited this paper, I got several notifications from them. Last one was this past Friday. Had no idea the retraction badge was a mistake.

Tweet Image 1

Lon S. Schneider, MD Reposted

@researchGate @RGsupport should retract their made-up retraction. least they could do. Maybe @ElsevierConnect @ElsevierNews @TheLancet should sue.😀


Yup, we’ve always suspected that Alzheimer pathology is mainly a plumbing problem — waste management.


Lon S. Schneider, MD Reposted

Always worth listening to what @LonSchneiderMD has to say about the interpretation of clinical trial data.

CONy 2024 News: Dorota Religa and Lon Schneider debate the issue of whether lecanemab treatment should be extended beyond 18 months. Read our coverage here.



Lon S. Schneider, MD Reposted

“They have retracted the retraction badge but say they can't tell those emailed despite our reputational damage.” Can’t or won’t?


Lon S. Schneider, MD Reposted

Sorry about this Gill. Have shared. Best wishes.


Lon S. Schneider, MD Reposted

Not sure what @ResearchGate is upto, but they have erroneously retracted @Gill_Livingston et al's @TheLancet paper on dementia ⬇️ twitter.com/Gill_Livingsto…

@@ResearchGate wrongly emailed out a retraction of our @TheLancet paper. They have retracted the retraction badge but say they can't tell those emailed despite our reputational damage. Please tell people. @ProfRobHoward @Naaheed_Mukadam @LonSchneiderMD thelancet.com/article/S0140-…



Lon S. Schneider, MD Reposted

@@ResearchGate wrongly emailed out a retraction of our @TheLancet paper. They have retracted the retraction badge but say they can't tell those emailed despite our reputational damage. Please tell people. @ProfRobHoward @Naaheed_Mukadam @LonSchneiderMD thelancet.com/article/S0140-…


Here’s a fun one. Poop out after 18 months in low tau subset?

Tweet Image 1

Loading...

Something went wrong.


Something went wrong.